dividend

Novartis (VTX:NOVN)

Discover the detailed analysis of Novartis, the pharmaceutical giant born from the merger of Ciba-Geigy and Sandoz, and its dividend policy that raises ethical and economic questions. Between job cuts and sustainable dividend growth, let's explore how this global leader in pharma balances its social responsibilities and financial performance.

Novartis (VTX:NOVN) Read More »

Dividends: Back to basics

In an insightful analysis published in Les Echos, Gilles Coville explores the resurgence of dividends as a pillar of investment, highlighting their historical importance and their crucial role in stock performance. This trend marks a return to normal according to David Shairp of JP Morgan AM, who highlights the reliability of dividends as an indicator of the financial health of companies and their appeal to investors seeking stable returns over the long term.

Dividends: Back to basics Read More »

Variability of dividend growth rates

Investors are particularly attracted to consistent dividends, as demonstrated by iconic companies such as PepsiCo, McDonald's and 3M, which have maintained consistent growth in their payouts. Analysis of these giants reveals that dividend growth can vary widely depending on economic cycles and corporate policies, but remains a key indicator for long-term investing.

Variability of dividend growth rates Read More »

Astrazeneca (NYSE:AZN)

AstraZeneca, the pharmaceutical giant born from the merger of Astra AB and Zeneca PLC, has established itself as one of the world leaders in the sector with around 100,000 employees dedicated to the research, development and marketing of pharmaceutical products. The group presents solid financial indicators, with an attractive yield and a generous dividend distribution policy, although investors should be cautious due to the relative youth of its successive dividend increases.

Astrazeneca (NYSE:AZN) Read More »